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Abstract
Background: HIV-associated tuberculosis (TB) co-infection remains an enormous burden to international public
health. Post-mortem studies have highlighted the high proportion of HIV-positive adults admitted to hospital with
TB. Determine TB-LAM and Xpert MTB/RIF assays can substantially increase diagnostic yield of TB within one day of
hospital admission. However, it remains unclear if this approach can impact clinical outcomes. The STAMP trial aims
to test the hypothesis that the implementation a urine-based screening strategy for TB can reduce all cause-
mortality among HIV-positive patients admitted to hospital when compared to current, sputum-based screening.
Methods: The trial is a pragmatic, individually randomised, multi-country (Malawi and South Africa) clinical trial with
two study arms (1:1 recruitment). Unselected HIV-positive patients admitted to medical wards, irrespective of
presentation, meeting the inclusion criteria and giving consent will be randomized to screening for TB using either:
(i) ‘standard of care’- testing of sputum using the Xpert MTB/RIF assay (Xpert) or (ii) ‘intervention’- testing of sputum
using Xpert and testing of urine using (a) Determine TB-LAM lateral-flow assay and (b) Xpert following
concentration of urine by centrifugation. Patients will be excluded if they have received TB treatment in the
previous 12 months, if they have received isoniazid preventive therapy in the last 6 months, if they are aged
<18 years or they live outside the pre-specified geographical area. Results will be provided to the responsible
medical team as soon as available to inform decisions regarding TB treatment. Both the study and routine medical
team will be masked to study arm allocation. 1300 patients will be enrolled per arm (equal numbers at the two trial
sites). The primary endpoint is all-cause mortality at 56 days. An economic analysis will be conducted to project
long-term outcomes for shorter-term trial data, including cost-effectiveness.
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Discussion: This pragmatic trial assesses an intervention to reduce the high mortality caused by HIV-associated TB,
which could feasibly be scaled up in high-burden settings if shown to be efficacious and cost-effective. We discuss
the challenges of designing a trial to assess the impact on mortality of laboratory-based TB screening interventions
given frequent initiation of empirical treatment and a failure of several previous clinical trials to demonstrate an
impact on clinical outcomes. We also elaborate on the practical and ethical issues of ‘testing a test’ in general.
Trial registration: ISRCTN Registry (ISRCTN71603869) prospectively registered 08 May 2015; the South African
National Controlled Trials Registry (DOH-27-1015-5185) prospectively registered October 2015.
Keywords: TB, HIV, HIV-associated TB, Screening, LAM, Xpert
Background
HIV-associated TB remains an enormous burden to
international public health, even in regions with high
coverage of antiretroviral therapy (ART). Globally, in
2014, there were an estimated 0.4 million TB related
deaths in people living with HIV, which accounts for ap-
proximately one-quarter of TB deaths and one-third of
HIV deaths [1]. This burden disproportionately affects
sub-Saharan Africa where TB is a common cause of hos-
pital admission and mortality among HIV-positive pa-
tients admitted to hospital [2].
Diagnosis of TB in people living with HIV remains
challenging due to non-specific clinical features, early
dissemination beyond the lungs and relatively low myco-
bacterial burden within sputum samples [3–5]. A meta-
analysis of post-mortem studies in adult HIV-positive
patients dying in hospitals in sub-Saharan Africa re-
ported that between 32 and 67 % (pooled summary esti-
mate 43 %) had evidence of TB at post-mortem [6]. TB
was disseminated in almost 90 % of patients, and
remained undiagnosed at the time of death in almost
one-half of TB cases, reflecting a failure of current spu-
tum and clinical based diagnosis of TB, and presenting a
strong rationale for routine systematic screening of HIV-
positive hospital admissions.
New diagnostic tools have been high on the TB research
agenda for the past decade, and are recognised as crucial
to the World Health Organization’s (WHO) End TB Strat-
egy [7]. The Xpert MTB/RIF rapid molecular assay (Xpert,
Cepheid, Sunnyvale, CA, USA) has a pooled sensitivity for
diagnosis of pulmonary TB in HIV-positive adults of 79 %
(95 % CI 70–86 %), with 99 % specificity. The test has
been approved by WHO and widely implemented in high
burden settings [8]. Systematic reviews have also reported
very high specificities for Xpert when testing a wide-
variety of non-respiratory clinical samples, despite culture
being an imperfect reference standard for extra-
pulmonary TB [9, 10]. Although data were insufficient for
the WHO guidelines to endorse the use of Xpert for TB
diagnosis from urine, studies have demonstrated useful
diagnostic yield and high specificity in urine among hospi-
talised HIV-positive patients [11–14].
Urine also has several advantages as a diagnostic sam-
ple for hospitalised HIV-positive patients, including rela-
tive ease of collection and lower biohazard risk during
specimen handling during collection and in the labora-
tory. The Determine TB-LAM (TB-LAM, Alere, Wal-
tham, MA, USA) lateral flow assay is a simple, point-of-
care test for detecting the mycobacterial cell wall antigen
lipoarabinomannan (LAM) in urine. It requires 60 μL of
unprocessed urine, giving a result in 25 min at a rela-
tively low cost (approximately US$2.50). Whilst sensitiv-
ity of this assay is poor in general populations, it is
improved in advanced HIV-related immunosuppression,
and studies in HIV-positive patients admitted to hospital
have demonstrated sensitivities between 40 and 70 %
[15–20]. Specificity is exceptionally high when the refer-
ence standards include culture of non-respiratory sam-
ples [19, 21]. TB-LAM was conditionally approved in
November 2015 by WHO for use in diagnosing TB in
hospitalised HIV-positive patients [22].
Evidence suggests that high mortality amongst hospi-
talised patients with HIV/TB co-infection is fuelled by
under-diagnosis of TB and delays in diagnosis due to
overreliance on sputum based diagnostics, imaging and/
or clinical features, and an inability to diagnose dissemi-
nated and extra pulmonary TB disease. We therefore
sought to evaluate the impact on mortality of a high-
yield, rapid-urine based screening approach for TB in
HIV-positive medical admissions to hospital in South
Africa and Malawi.
Rationale for studies of clinical impact
A study from South Africa intensively screened unse-
lected HIV-positive hospital admissions to medical
wards with comprehensive clinical sampling (sputum,
blood, urine and other clinically relevant samples) [14].
Using mycobacterial liquid culture and/or Xpert, TB was
diagnosed in 139/427 patients (33 % TB prevalence,
95 % CI 28–37 %). However, only 28 % of microbiologic-
ally confirmed TB in this study could have been diag-
nosed by Xpert testing of sputum alone. In contrast,
81 % of TB cases could have been diagnosed by Xpert
testing of both sputum and urine, with additional TB-
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LAM testing of urine, and results are available within
the first 24 h of hospital admission [14, 23]. Xpert is the
best diagnostic test available in most high-burden set-
tings and the WHO’s recommended initial TB test for
HIV-positive patients. The use of this rapid, relatively
low cost screening approach increased diagnostic yield
by almost three-fold.
Despite this increase in diagnostic yield, there is no
evidence that this urine-based screening strategy will im-
pact mortality or clinical outcomes; it is recommended
that impact be demonstrated before such interventions
can be endorsed or implemented [24]. This is especially
true, as numerous studies have noted that the replace-
ment of sputum smear-microscopy with the more sensi-
tive Xpert has failed to demonstrate any impact on
clinical outcomes [25]. A recently published randomised
controlled trial of adjunctive urine testing with the TB-
LAM assay (the LAM RCT) in a selected population of
hospitalised HIV-positive patients being investigated for
TB demonstrated an absolute mortality reduction of 4 %
(95%CI 1–7 %) and a relative reduction in mortality of
17 % (95%CI 4–27 %). These data support the potential
for a urine-based screening approach to reduce mortality
among unselected HIV-positive in-patients [26].
Rationale for a Randomized Controlled Trial (RCT)
Whilst a high yield, urine-based screening strategy might
benefit this patient population by increasing the number
of TB diagnoses and decreasing time to TB treatment, it
may also be associated with a range of adverse conse-
quences. A rapid TB diagnosis within the first 1–2 days
of hospital admission may divert clinical attention from
co-pathologies, and may reduce the likelihood of empir-
ical prescription of antibiotics for occult bacterial infec-
tions. Further, despite excellent specificity, this screening
approach may lead to some false-positive TB diagnoses
and false-positive rifampicin resistance results from
Xpert assays, leading to inappropriate use of potentially
harmful medication. Although relatively low cost, the
implementation of such a screening strategy will require
investment of limited health service resources, and may
divert resources from other interventions with poten-
tially greater impact on health outcomes.
Although diagnostic tests are routinely implemented
on the basis of diagnostic accuracy or effectiveness with-
out assessment of impact on clinical outcomes (e.g.
Xpert and rapid malaria diagnostics), their impact on
population health is part of a wider cascade of processes
including care seeking and initiation of appropriate
treatment [27]. Thus, they should be evaluated under
such circumstances too, and evidence of diagnostic ac-
curacy alone should not be taken as evidence of impact
on patient-appropriate outcomes such as reducing mor-
bidity or mortality [27]. This is especially true of TB
diagnostics, as even mycobacterial culture (the most sen-
sitive diagnostic) can have minimal impact on clinical
decision to initiate TB treatment [28].
Methods/Design
Aim
The principal aim of this trial is to test the hypothesis
that the implementation of a rapid, sensitive urine-based
screening strategy for TB can reduce all cause-mortality
among HIV-positive patients admitted to hospitals in
sub-Saharan Africa when compared to current, sputum-
based screening.
Study design
The trial is a pragmatic, individually randomised, multi-
country clinical trial with two study arms with 1:1 allo-
cation between arms (Fig. 1). HIV-positive patients ran-
domised to the ‘standard of care’ arm will be screened
for TB by testing sputum (if produced by spontaneous
expectoration) using the Xpert assay. HIV-positive
patients randomised to the intervention arm will, in
addition to the standard of care, have a urine sample (if
produced) tested for TB using the TB-LAM assay and,
following concentration of 40–50mls of urine by centri-
fugation, the Xpert assay. Patients, the responsible med-
ical team and study team will be masked to the study
arm allocation (except for the study statistician, data
managers and laboratory technicians). TB screening test
results will be communicated to the medical teams re-
sponsible for clinical care of the patients (whilst main-
taining masking to study arm allocation), but the clinical
management decisions informed by the test results, in-
cluding whether to commence TB treatment, will not be
altered by the study team. Beyond collection of TB
screening samples, running of assays and issuing of
results, the study team will have no involvement in the
clinical care of participants.
Study population
The trial will take place at two sites: Zomba Central
Hospital, Southern Malawi, and Edendale Hospital,
KwaZulu-Natal, South Africa. Both hospitals serve popu-
lations with high HIV prevalence and TB incidence.
All new admissions to medical wards who have con-
firmed HIV-infection (either an existing or new diagno-
sis), irrespective of antiretroviral therapy (ART) status,
will be screened for eligibility. HIV testing of all hospital
admissions with unknown HIV-status is recommended
as part of national guidelines at both trial sites, and will
be supported by study staff where necessary. Eligibility
criteria are designed to be as broad as possible. Patients
will be eligible for inclusion regardless of reason for
medical admission or presence of TB symptoms (unse-
lected), although patients <18 years old, those who have
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received TB treatment in the preceding 12 months or
isoniazid preventive therapy in the preceding 6 months,
those unable to provide informed consent or living out-
side a pre-defined geographical area will be excluded. It
is envisaged that recruitment will take place over a
period of 24 months, with equal numbers recruited at
each study site.
Study procedures
After obtaining written informed consent from eligible
patients, a study nurse will collect data at baseline to de-
termine clinical history, including TB symptoms, past
history of TB and HIV care, vital signs and nutritional
and performance status. Venepuncture for haemoglobin
concentration and CD4 cell count will be conducted and
single sputum sample and up to 50mls of urine will be
collected from all participants, irrespective of study arm.
If sputum and/or urine samples cannot be spontaneously
produced, participants will remain in the study but no
further samples for TB investigation will be arranged by
the study team. However, the responsible medical team
will remain at liberty to arrange further TB investiga-
tions that are available as standard of care at the study
hospital.
A randomisation list stratified by study site using com-
puter generated random block size will be generated.
Randomisation will occur at enrolment, but the study
team will be masked to study arm allocation. When TB
samples (sputum and/or urine) from participants arrive
in the laboratory, the study laboratory technician will
identify the allocated study arm by opening a sealed en-
velope marked with the unique participant ID, and de-
termine which samples will be screened for TB. Urine
from participants randomised to the standard of care
arm will not be tested for TB and will be safely dis-
carded. TB-LAM assays will be read by the laboratory
Fig. 1 Study design flow diagram
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technician and results will be deemed as positive using
the grade 1 cut-off on the manufacturer’s reference card.
20 % of TB-LAM assays will read by a second, blinded
reader for quality control.
TB screening tests will only be processed during office
working hours on weekdays. Once the TB screening tests
have been completed (anticipated to be within 24-48 h of
sample collection), the results will be issued whilst main-
taining masking of the study arm and responsible medical
teams (reported as either ‘TB screening test positive’, ‘TB
screening test negative’ or ‘TB screening test not done’).
Rifampicin resistance results, when available, will also be
communicated to the medical teams.
The responsible medical team will receive training on
how to interpret the screening tests, including estimated
positive and negative predictive values of the screening
algorithms in each study arm, and that a negative
screening test does not ‘rule out’ TB. The responsible
medical team will be at liberty to organise further TB in-
vestigations and commence TB treatment as clinically
appropriate. Management of HIV will be as per local
and national guidelines, including timing of ART initi-
ation. Data on TB investigations, diagnoses (including if
microbiologically confirmed or ‘empirical’) and treat-
ment will be collected during follow-up.
Outcomes
The primary outcome is risk of all-cause mortality at 56-
days following enrolment. Secondary outcomes are: time
to all-cause mortality; proportions of patients with (i)
microbiologically confirmed and (ii) clinically diagnosed
TB disease; time to TB diagnosis and commencement of
TB treatment; proportions of patients receiving antimi-
crobials and ART; and (i) duration of hospital admission,
(ii) cumulative incidence of hospital readmission, and
(iii) cumulative incidence of loss to follow-up. Outcomes
will be ascertained by patient interview and review of
medical notes during in-patient admission, and patient
interview for vital status at 56-days post enrolment. This
will be supplemented with information from patients’
next of kin for those lost to follow-up.
Microbiologically confirmed TB is defined as at least
one positive smear-microscopy, Xpert, or culture posi-
tive result on any specimen or a positive urine TB-LAM
result. Clinically diagnosed TB is defined as having a
compatible clinical illness or radiological disease and/or
the decision of the responsible clinical team to com-
mence TB treatment in the absence of any positive
microbiological tests for TB.
Economic analysis
An economic analysis from a societal perspective will be
undertaken to demonstrate the longer-term clinical and
budgetary impact as well as the cost-effectiveness of the
intervention; demonstrating economic feasibility and
cost-effectiveness will be essential prior to implementa-
tion, should this screening intervention prove effective.
Given the complexities of diagnosis and treatment of
HIV/TB coinfection for patients requiring hospital ad-
mission, we will estimate health service costs based upon
resource utilization of trial participants, inclusive of
laboratory reagents and services, inpatient
hospitalization days and outpatient visits, as well as drug
costs. Trial-site specific costs will be collected on a lim-
ited cohort of 100 participants per site. We anticipate
that, in the short term, costs of hospital admission are
likely to account for a large proportion of health service
provider expenditure; over the longer term, we expect
increased survival related to the intervention will result
in greater cumulative antiretroviral drug costs. Longer
term cost-effectiveness will be estimated based on the
Cost-Effectiveness of Preventing AIDS Complications-
International (CEPAC-I) computer simulation model
[29]. Model-based outcomes will include a short-term
validation of trial results; that is, we will ensure that
model results after 2 months of simulation accurately re-
flect trial outcomes of 56 days. Longer-term model re-
sults will include: 1-year and 5-year survival, TB-deaths
averted, overall deaths averted and per person costs as
well as life expectancy (LE) and lifetime costs. At each
time horizon (1-year, 5-year and lifetime), the incremen-
tal cost-effectiveness of the intervention compared with
the standard of care (Δ$/ΔLE, both discounted by 3 %
per year) will be calculated. Model results will be exam-
ined in one-way and multi-way deterministic sensitivity
analyses, examining influential parameters of interest
(e.g. mean CD4 at presentation, TB screening test sensi-
tivity/specificity and cost, active TB prevalence on
admission). In addition to cost-effectiveness analyses, the
budgetary impact of implementation and scale-up at
1- and 5- years of this intervention will be reported.
Sample size justification
Sample size calculations were based upon unpublished
data from the trial sites, which showed a mortality of
HIV-positive medical in-patients of 21–23 % during hos-
pital admission and are supported by subsequently pub-
lished meta-analyses on hospitalised HIV-positive
patients in Africa [2, 30]. We assumed that 56-day mor-
tality would be 25–30 % in the standard of care arm
and, based upon post-mortem prevalence of TB, we esti-
mated 40–50 % of deaths in the standard of care arm
would be TB-related.
The sensitivity of the intervention for diagnosing TB
disease was assumed to be 80 % (a 3-fold increase in
diagnostic yield compared to sputum alone) based upon
a background study [14]. An observational study of
early-initiation of TB treatment among HIV-positive
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smear-negative hospital in-patients observed a reduction
in mortality at 2-months of 47 % in patients whose TB
treatment was expedited by use of WHO-recommended
diagnostic algorithm compared to standard practice [31].
Our study was powered to detect a 40–50 % reduction
in TB-related mortality, and assuming half of deaths are
TB related, this would equate to a 20–25 % reduction in
all-cause mortality. Our sample size of 1300 patients per
arm would provide 90 % power to detect a 25 % reduc-
tion in mortality and 80 % power to detect a 20 % reduc-
tion in mortality, assuming an all-cause mortality of
25 % in the ‘standard of care’ arm and a 2-sided type 1
error of 5 % and 10–15 % loss to follow-up. If the 56-day
mortality was unexpectedly lower (20 %) in the standard
of care arm, our sample size would still provide 80 %
power to detect a 25 % reduction in all-cause mortality.
Data collection and management
Data will be collected at four main times: enrolment, dur-
ing the hospital admission, at hospital discharge and at the
56-day follow-up visit (Table 1). Specially designed case
report forms are completed by study staff at each time
point, and scanned, verified and committed to a local site
database within 48 h of completion using the optical-
character-recognition software TeleForm (Hewlett
Packard Software, CA, USA). All data in critical fields are
verified upon scanning. Completed forms are stored as the
source documentation in a locked cabinet, with access
restricted to specified study team members. Locator
information is stored separately to other case report forms
which are identified by unique participant ID number and
do not contain any patient identifiable information.
Queries based on data in the database are generated
weekly, including date, range and logic checks, and sent to
sites for resolution.
Follow-up at 56-days is undertaken through outpatient
appointment attendance at the study site. If participants
are unable to attend the outpatient appointment, they
are traced by telephone and/or home visit if they have
provided prior consent for this to occur. Participants are
defined as lost to follow-up if they are unable to be con-
tacted after three tracing attempts after 56-days from
enrolment. Quality assurance processes are in place to
check all consent forms, screening case report forms,
laboratory case report forms and a random sub-sample
of all other case report forms.
Statistical analysis
The trial profile will be summarised using a CONSORT
flow chart, including reasons for non-eligibility and non-
enrolment (Fig. 2) [32]. All analyses will be conducted
by initially assigned study arm in an intention-to-treat
analysis, and adjusted for randomisation site. Baseline
variables will be presented by study arm.
For the primary outcome the risk difference and odds
ratio, and their associated 95 % confidence intervals for
the effect of study arm on mortality risk will be calcu-
lated. The primary analysis of this endpoint will assume
Table 1 Schedule of STAMP study activities
Time-point: Enrolment Baseline
assessment
TB testing In-patient
stay
Hospital exit Outpatient Review
Time On-Study: Day 0 Day 0 Day 0–1 Day 0+ Day 0+ Day 56
Enrolment:
Eligibility Screen X
Informed consent X
HIV confirmation X
Study arm allocation X
Interventions:
Collect admission specimens (blood, sputum
and urine)
X
TB screening & issuing results X
Assessments:
Baseline demographic and clinical information X
EQ5D X X
TB investigations, diagnosis and/or treatment X X X
Vital status X X X
HIV care/ART X X X
Health service use X X X
EQ5D quality of life questionnaire [38]
ART antiretroviral therapy
Gupta-Wright et al. BMC Infectious Diseases  (2016) 16:501 Page 6 of 11
participants who are lost to follow-up before 56 days
have not died. Sensitivity analyses will be conducted to
assess assumptions made regarding missing data and pa-
tients lost to follow-up. A sub-group analysis of the pri-
mary outcome will be conducted for the following
variables: study site, calendar time, baseline CD4 cell
count (<100 or >100 cells/μL), presence of severe an-
aemia (Hb <80 g/L) and clinically suspected TB at ad-
mission. The interaction effects by subgroup will be
investigated and p-values reported.
Secondary outcomes (as defined above) will be com-
pared between study arms using logistic regression for
binary outcome and survival analysis with Kaplan-Meier
curves and Cox proportional hazards for time to event.
All analyses will be adjusted for randomisation site.
A statistical analysis plan documents the analysis of all
trial outcomes in detail, and was reviewed by the Data
Safety and Monitoring Board (DSMB).
Trial governance and approvals
The trial will be governed by a Trial Steering Committee
(TSC), including an independent chairperson and at
least three other independent members. The TSC will
oversee the trial and advise the investigator team, includ-
ing monitoring progress, receiving reports from the Data
and Safety Monitoring Board (DSMB), and assessing the
impact of new scientific evidence. The DSMB’s role is to
protect the safety of trial participants, they will meet
every six months to review data from the trial, as set out
in the DSMB charter, and are independent to the trial
sponsor (the London School of Hygiene & Tropical
Medicine). Monitoring visits will be undertaken at least
three-monthly for quality assurance and to ensure ad-
herence to the trial protocol, and auditing of the trial
conduct will be undertaken by the trial sponsor.
The trial has also received approval from the Research
Ethics Committees of the London School of Hygiene &
Tropical Medicine (ref: 9630), College of Medicine
University of Malawi (ref: P.06/15/1743) and the
University of KwaZulu-Natal Biomedical Research Ethics
Committee (ref: BFC215/15). STAMP is registered with
the ISRCTN Registry (ref: ISRCTN71603869) and the
South African National Controlled Trials Registry (ref:
DOH-27-1015-5185). The trial is funded by the Joint
Fig. 2 CONSORT flow diagram
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Global Health Trials scheme (a collaboration between
the UK Department for International Development, the
UK Medical Research Council and the Wellcome Trust),
and was peer reviewed as part of the funding application
process.
Discussion
The STAMP trial aims to assess whether a novel, rapid
urine-based screening strategy for TB with a high diag-
nostic yield can reduce early mortality in HIV-positive
patients admitted to hospital in sub-Saharan Africa. The
need for this trial is clear given the high mortality
among HIV-positive patients admitted to hospital in
these settings, and the high proportion of patients that
die with undiagnosed TB disease [6, 30]. Positive urine-
based TB diagnostic tests in advanced HIV are a marker
of haematogenously disseminated renal TB, and these
patients are at higher risk of mortality, supporting the
rationale that earlier diagnosis and treatment may re-
duce mortality [33, 34].
Other trials have assessed empirical TB treatment in
HIV-positive patients at high risk of TB, although mostly
in outpatient settings. The REMEMBER trial failed to
demonstrate a mortality benefit of empirical TB treat-
ment compared to isoniazid preventive therapy [35].
The TB Fast Track trial assessed an algorithm using
body mass index, presence of anaemia and urine TB-
LAM testing to identify HIV-positive ambulatory
patients with CD4 cell counts ≤150 cells/μL at high risk
of TB in whom empirical TB treatment was started
immediately, but found no reduction in 6-month mortal-
ity compared to the standard of care [34, 35]. The
STAMP investigators believe that utilising new TB diag-
nostics can provide better specificity than empirical TB
treatment and prevent the potential harm from prescrip-
tion of TB treatment to HIV-positive patients without
TB disease among hospital inpatients.
A trial of adjunctive urine testing with the TB-LAM
assay in a selected population of hospitalised HIV-
positive patients being investigated for TB (the LAM
RCT) recently demonstrated a reduction in mortality at
2-months [26]. The STAMP trial differs from this RCT
in respect to several factors. Firstly, the inclusion criteria
differ in that STAMP is a screening intervention target-
ing unselected HIV-positive patients admitted to hos-
pital regardless of clinical presentation, and the LAM
RCT investigated the TB-LAM diagnostic in hospitalised
HIV-positive patients who were presumed to have TB.
As such, STAMP has the potential to detect TB among
those without any clinical suspicion for TB on hospital
entry. Secondly, the STAMP intervention includes the
Xpert MTB/RIF assay performed on urine in addition to
TB-LAM, whereas LAM RCT evaluated urine testing
with TB-LAM alone. This increases the diagnostic yield
of the intervention and adds the potential to diagnose ri-
fampicin resistance. Thirdly, the standard of care in the
STAMP trial includes Xpert testing of sputum (if pro-
duced) at all study sites, whilst the standard of care in
LAM RCT varied from easy access to Xpert in South
Africa to no access to Xpert in Zimbabwe. Finally, in the
STAMP trial but not in the LAM RCT, both study teams
and routine medical teams managing patients are
masked to the study intervention arm (i.e. which TB
screening tests are done).
The rationale for a clinical trial to demonstrate impact
prior to implementation is supported by the lack of dem-
onstrable benefit upon patient outcomes of sputum
screening using Xpert in HIV-positive patients, despite in-
creases in diagnostic yield compared to sputum smear mi-
croscopy [25]. Reasons for the failure of such trials of
Xpert sputum testing to demonstrate impact may include
lower occurrence of mortality endpoints in populations
studies (largely outpatient based studies), high rates of em-
pirical TB treatment and the failure of some positive Xpert
results to be translated to TB treatment due to delays be-
tween submission of samples and issuing of results. The
decision to start TB treatment is complex, and in such tri-
als is likely to be influenced by the premise of the study to
reduce undiagnosed, or ‘missed’ TB cases, potentially in-
creasing empirical TB treatment [36].
These issues have been considered when designing the
STAMP trial. For example, in-patient settings have a
high mortality, and initiating TB treatment following
positive results is more likely to occur when patients are
admitted to hospital compared to community settings.
Masking of clinicians, investigators and patients to the
study intervention arm should reduce any ‘Hawthorne’
effect which could increase empirical TB treatment in
the standard of care arm due to clinicians observing
higher diagnostic yield in the intervention arm [37]. The
use of ‘double-blinding’ in this manner is unusual in as-
sessments of diagnostics, and, to our knowledge, this is
the first time it has been used in TB diagnostics. How-
ever, a disadvantage of masking is that it might impair
the ability of clinicians to make decisions about TB
treatment in the absence of a positive screening result.
The STAMP trial sites have also been chosen to repre-
sent differing facilities, cadre of healthcare workers and
resource utilisation in the region. Two studies to date,
including one RCT, have demonstrated decreases in
early mortality from expedited TB treatment in hospita-
lised HIV-positive patients, supporting the STAMP trial
hypothesis that urine-based screening could reduce mor-
tality [26, 31].
The unique challenges of ‘testing a test’ have also been
considered in the STAMP study design, in particular, re-
garding the ethics of conducting such a trial. If consider-
ing the diagnostic accuracy or yield of the STAMP study
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intervention compared to sputum screening or clinical
diagnosis alone, [14] it could be argued there is a lack of
equipoise (i.e. disagreement about the relative merits of
the intervention). Whilst equipoise may not exist for
diagnostic accuracy of the intervention for detecting
HIV-TB, equipoise clearly exists for the impact of the
study intervention on early mortality in unselected HIV-
positive hospital admissions when compared to the spu-
tum and clinical screening strategies that are current
standard of care [27]. We have also considered the po-
tential negative consequences of a rapid microbiological
TB diagnosis, such as delay in initiating ART, a reduc-
tion in the prescription of empirical antibiotics which
may treat covert sepsis in this severely immunosup-
pressed population and false-positive rifampicin resist-
ance results. This study will be able to describe and
document the impact of these potential harms and com-
pare these secondary endpoints between study arms.
Furthermore, the pragmatic nature of the STAMP
trial, with clinical care including TB diagnostics outside
the study intervention, TB treatment and ART under
routine conditions for each study setting, make the find-
ings more generalisable and applicable to scale up. The
wide inclusion criteria and not restricting TB testing to
patients with ‘presumptive’ TB (for which the definition
often varies between settings) also makes the results
more applicable. The recently published WHO guidance
on the use of LAM lateral flow assays advises against its
use for screening, based upon low quality evidence [22].
The STAMP study can provide randomised trial quality
evidence to support or refute these recommendations
for HIV-positive, hospitalised patients. The study inter-
vention should be possible to replicate in resource-
limiting settings given the widespread availability of the
Xpert assay and lack of equipment required for the TB-
LAM testing, in keeping with STAMP being a pragmatic
trial. The concentration of urine prior to testing with the
Xpert assay (which has been shown to increase sensitiv-
ity [14]) is done using a bucket centrifuge. Laboratory
based research is also being undertaken to look for alter-
native, lower resource methods to concentrate urine
prior to testing with Xpert.
The STAMP trial acknowledges the potential disad-
vantages of urine-based TB screening for this popula-
tion, especially the cost implications. Although the
intervention is relatively low-cost, health budgets in high
TB and HIV settings are limited, and therefore wide-
spread implementation of the STAMP study interven-
tion may have substantial budgetary impact. The
STAMP trial incorporates an economic analysis which
will assess cost-effectiveness of the study intervention
from a societal prospective and will include an analysis
of budgetary impact of scale-up of this intervention.
Should the intervention prove both effective and cost-
effective, these analyses will assist in motivating the
financial resources to promote its implementation.
In summary, the STAMP trial is assessing a novel,
urine-based screening strategy utilising the TB-LAM
and Xpert assays in HIV-positive patients admitted to
hospital in sub-Saharan Africa. We hypothesise that use
of this screening algorithm will reduce all-cause mortal-
ity at 2 months compared to sputum and clinical diag-
nostics (using the Xpert assay) which is the standard of
care as currently recommended by the WHO. The trial
commenced recruitment of patients in October 2015,
and is projected to complete recruitment by September
2017 and follow-up by November 2017.
Abbreviations
ART: Antiretroviral therapy; CEPAC-I: Cost-Effectiveness of Preventing AIDS
Complications-International; DSMB: Data Safety and Monitoring Board;
HIV: Human immunodeficiency virus; LAM: Lipoarabinomannan; LE: Life
expectancy; RCT: Randomized Controlled Trial; TB: Tuberculosis; WHO: World
Health Organization
Acknowledgements
TSC members: Anthony Harries*, Andy Ramsay*, Frank Cobelens*, Bibi Oni*,
Stephen Lawn, Katherine Fielding, Joep van Oosterhout, Doug Wilson, Liz
Corbett, Ankur Gupta-Wright
DSMB members: Andrew Nunn*, Anton Pozniak*, Tom Harrison*, Katherine
Fielding, Clare Flach, Stephen Lawn, Ankur Gupta-Wright
*independent members
Funding
This trial is funded by a Joint Global Health Trials scheme grant from the
MRC/DFID/Wellcome Trust (STAMP Trial; grant no. MR/M007375/1). AGW is
also funded by the Royal College of Physicians, London, UK (JMGP
fellowship). The funders do not have any direct roles in the design or
conduct of this trial, but request regular reporting of progress for routine
grant/trial administration.
Availability of data and materials
Final study datasets will be stored locally and securely at the London School of
Hygiene & Tropical Medicine for long-term storage and access. Anonymised
participant level data will be made available by request on a case-by-case basis.
Authors’ contributions
SDL (chief-investigator) conceived the study and acquired funding with
ELC, KF, JvO and DW. AGW wrote the first draft of the manuscript. RW
and KR revised and augmented the methodological detail of the
economic analysis section. KF, DW and JvO reviewed and refined the
draft. All co-authors contributed to review and refinement of the
manuscript, and read and approved the final version.
Competing interests
The authors declare that they have no competing interests
Consent for publication
Not applicable
Ethics approval and consent to participate
This trial protocol has been approved by the Research Ethics Committees of
the London School of Hygiene & Tropical Medicine (ref: 9630), College of
Medicine University of Malawi (ref: P.06/15/1743) and the University of
KwaZulu-Natal Biomedical Research Ethics Committee (ref: BFC215/15). All
patients in the trial will provide informed written consent to participate.
Author details
1Department of Clinical Research, London School of Hygiene & Tropical
Medicine, London, UK. 2Malawi-Liverpool-Wellcome Trust Clinical Research
Program, University of Malawi College of Medicine, Blantyre, Malawi.
Gupta-Wright et al. BMC Infectious Diseases  (2016) 16:501 Page 9 of 11
3Department of Infectious Disease Epidemiology, London School of Hygiene
& Tropical Medicine, London, UK. 4University of the Witwatersrand,
Johannesburg, South Africa. 5Dignitas International, Zomba, Malawi.
6Department of Medicine, College of Medicine, University of Malawi, Blantyre,
Malawi. 7Department of Internal Medicine, Edendale Hospital, University of
KwaZulu-Natal, Pietermaritzburg, South Africa. 8Division of Pulmonary and
Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA.
9Divisions of General Medicine and Infectious Disease, Massachusetts General
Hospital, Boston, MA, USA. 10The Medical Practice Evaluation Center,
Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
11Harvard University Center for AIDS Research, Harvard Medical School,
Boston, MA, USA. 12The Desmond Tutu HIV Centre, Institute of Infectious
Disease and Molecular Medicine, Faculty of Health Sciences, University of
Cape Town, Cape Town, South Africa.
Received: 13 August 2016 Accepted: 16 September 2016
References
1. World Health Organization. Global Tuberculosis Report 2015. Geneva: World
Health Organization; 2015.
2. Ford N, Matteelli A, Shubber Z, Hermans S, Meintjes G, Grinsztejn B, Waldrop
G, Kranzer K, Doherty M, Getahun H. TB as a cause of hospitalization and in-
hospital mortality among people living with HIV worldwide: a systematic
review and meta-analysis. J Int AIDS Soc. 2016;19(January 2007):20714.
3. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in
people with HIV in resource-limited settings. Lancet Infect Dis. 2009;9:173–84.
4. Elliott AM, Halwiindi B, Hayes RJ, Luo N, Tembo G, Machiels L, Bem C,
Steenbergen G, Pobee JO, Nunn PP. The impact of human
immunodeficiency virus on presentation and diagnosis of tuberculosis in a
cohort study in Zambia. J Trop Med Hyg. 1993;96:1–11.
5. Gilks CF, Brindle RJ, Otieno LS, Bhatt SM, Newnham RS, Simani PM, Lule GN,
Okelo GB, Watkins WM, Waiyaki PG. Extrapulmonary and disseminated
tuberculosis in HIV-1-seropositive patients presenting to the acute medical
services in Nairobi. AIDS. 1990;4:981–5.
6. Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in
post-mortem studies of HIV-infected adults and children in resource-limited
settings: a systematic review and meta-analysis. AIDS. 2015;29:1987–2002.
7. World Health Organization. Global Strategy and Targets for Tuberculosis
Prevention, Care and Control after 2015. Geneva: World Health
Organization; 2014.
8. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert®
MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in
adults. Cochrane Database Syst Rev. 2014;1:CD009593.
9. Maynard-Smith L, Larke N, Peters JA, Lawn SD. Diagnostic accuracy of the
Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when
testing non-respiratory samples: a systematic review. BMC Infect Dis. 2014;
14:709.
10. Denkinger CM, Schumacher SG, Boehme CC, Dendukuri N, Pai M, Steingart
KR. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a
systematic review and meta-analysis. Eur Respir J. 2014;44:435–46.
11. World Health Organization. Automated Real-Time Nucleic Acid
Amplification Technology for Rapid and Simultaneous Detection of
Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF Assay for the
Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children.
Policy Update. Geneva: World Health Organization; 2014.
12. Peter JG, Theron G, Muchinga TE, Govender U, Dheda K. The diagnostic
accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients
who are smear-negative or sputum scarce. PLoS One. 2012;7:e39966.
13. Lawn SD, Kerkhoff AD, Vogt M, Wood R. High diagnostic yield of
tuberculosis from screening urine samples from HIV-infected patients with
advanced immunodeficiency using the Xpert MTB/RIF assay. J Acquir
Immune Defic Syndr. 2012;60:289–94.
14. Lawn SD, Kerkhoff AD, Burton R, Schutz C, van Wyk G, Vogt M, Pahlana P,
Nicol MP, Meintjes G. Rapid microbiological screening for tuberculosis in
HIV-positive patients on the first day of acute hospital admission by
systematic testing of urine samples using Xpert MTB/RIF: a prospective
cohort in South Africa. BMC Med. 2015;13:192.
15. Manabe YC, Nonyane BAS, Nakiyingi L, Mbabazi O, Lubega G, Shah M,
Moulton LH, Joloba M, Ellner J, Dorman SE. Point-of-care lateral flow assays
for tuberculosis and cryptococcal antigenuria predict death in HIV infected
adults in Uganda. PLoS One. 2014;9:e101459.
16. Bjerrum S, Kenu E, Lartey M, Newman MJ, Addo KK, Andersen AB, Johansen
IS. Diagnostic accuracy of the rapid urine lipoarabinomannan test for
pulmonary tuberculosis among HIV-infected adults in Ghana–findings from
the DETECT HIV-TB study. BMC Infect Dis. 2015;15:407.
17. Shah M, Variava E, Holmes CB, Coppin A, Golub JE, McCallum J, Wong M,
Luke B, Martin DJ, Chaisson RE, Dorman SE, Martinson NA. Diagnostic
accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized
patients in a High HIV prevalence setting. J Acquir Immune Defic Syndr.
2009;52:145–51.
18. Talbot E, Munseri P, Teixeira P, Matee M, Bakari M, Lahey T, von Reyn F. Test
characteristics of urinary lipoarabinomannan and predictors of mortality
among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS
One. 2012;7:e32876.
19. Lawn SD, Kerkhoff AD, Burton R, Vogt M, Pahlana P, Nicol MP, Meintjes G.
Systematic investigation for tuberculosis in HIV-infected patients on the first
day of admission to a South African hospital: incremental diagnostic yield,
accuracy and prognostic value of a urine LAM lateral-flow assay. In. 45th
World Conference on Lung Health of the International Union Against
Tuberculosis and Lung Disease (The Union). Barcelona, Spain; 2014:HIV Late
Breaker Oral Presentation (HIV_LB04).
20. Peter JG, Theron G, Dheda K. Can point-of-care urine LAM strip testing for
tuberculosis add value to clinical decision making in hospitalised HIV-
infected persons? PLoS One. 2013;8:e54875.
21. Lawn SD, Dheda K, Kerkhoff AD, Peter JG, Dorman S, Boehme CC, Nicol MP.
Determine TB-LAM lateral flow urine antigen assay for HIV-associated
tuberculosis: recommendations on the design and reporting of clinical
studies. BMC Infect Dis. 2013;13:407.
22. World Health Organization. The Use of Lateral Flow Urine Lipoarabinomannan
Assay (LF-LAM) for the Diagnosis and Screening of Active Tuberculosis in
People Living with HIV: Policy. Geneva: World Health Organization; 2015.
23. Lawn SD, Kerkhoff AD, Burton R, Scutz C, van Wyk G, Vogt M, Pahlana P,
Nicol M, Meintjes G. Massive Diagnostic Yield of HIV-Associated Tuberculosis
Using Rapid Urine Diagnostic Assays in South Africa. In: Program and
Abstracts of the Conferences on Retroviruses and Opportunistic Infections
(CROI). 2014. Abstract #2813.
24. Langley I, Doulla B, Lin H-H, Millington K, Squire B. Modelling the impacts of
new diagnostic tools for tuberculosis in developing countries to enhance
policy decisions. Health Care Manag Sci. 2012;15:239–53.
25. McNerney R, Zumla A. Impact of the Xpert MTB/RIF diagnostic test for
tuberculosis in countries with a high burden of disease. Curr Opin Pulm
Med. 2015;21:304–8.
26. Peter JG, Zijenah LS, Chanda D, Clowes P, Lesosky M, Gina P, Mehta N,
Calligaro G, Lombard CJ, Kadzirange G, Bandason T, Chansa A, Liusha N,
Mangu C, Mtafya B, Msila H, Mtafya B, Rachow A, Hoelscher4 M, Mwaba3 P,
Theron G, Dheda K. The mortality impact of point-of-care urine
lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-
infected hospitalised patients: a multi-country randomised controlled trial.
Lancet. 2016, in press:1–11.
27. Dowdy DW, Gounder CR, Corbett EL, Ngwira LG, Chaisson RE, Merritt MW.
The ethics of testing a test: randomized trials of the health impact of
diagnostic tests for infectious diseases. Clin Infect Dis. 2012;55:1522–6.
28. Stall N, Rubin T, Michael JS, Mathai D, Abraham OC, Mathews P, Thomas K,
John M, Daley P. Does solid culture for tuberculosis influence clinical
decision making in India? Int J Tuberc Lung Dis. 2011;15:641–6.
29. Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD,
Nakamura YM, Godbole SV, Panchia R, Sanne I, Weinstein MC, Losina E,
Mayer KH, Chen YQ, Wang L, McCauley M, Gamble T, Seage GR, Cohen MS,
Freedberg KA. Cost-effectiveness of HIV treatment as prevention in
serodiscordant couples. N Engl J Med. 2013;369:1715–25.
30 Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ, Davies
M-A, Vitoria M, Penazzato M, Nsanzimana S, Frigati L, O’Brien D, Ellman
T, Ajose O, Calmy A, Doherty M. Causes of hospital admission among
people living with HIV worldwide: a systematic review and meta-
analysis. Lancet HIV. 2015;2:e438–44.
31 Holtz TH, Kabera G, Mthiyane T, Zingoni T, Nadesan S, Ross D, Allen J,
Chideya S, Sunpath H, Rustomjee R. Use of a WHO-recommended
algorithm to reduce mortality in seriously ill patients with HIV infection and
smear-negative pulmonary tuberculosis in South Africa: an observational
cohort study. Lancet Infect Dis. 2011;11:533–40.
Gupta-Wright et al. BMC Infectious Diseases  (2016) 16:501 Page 10 of 11
32 Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated
guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.
33 Lawn SD, Gupta-Wright A. Detection of Lipoarabinomannan (LAM) in urine
is indicative of disseminated tuberculosis with renal involvement in patients
living with HIV and advanced immunodeficiency: evidence and
implications. Trans R Soc Trop Med Hyg. 2016;110:180–5.
34 Gupta-wright A, Peters JA, Flach C, Lawn SD. Detection of
lipoarabinomannan (LAM) in urine is an independent predictor of mortality
risk in patients receiving treatment for HIV-associated tuberculosis in sub-
Saharan Africa : a systematic review and meta-analysis. BMC Med. 2016;14:
53. doi:10.1186/s12916-016-0603-9.
35 Hosseinipour MC, Bisson GP, Miyahara S, Sun X, Moses A, Riviere C, Kirui FK,
Badal-Faesen S, Lagat D, Nyirenda M, Naidoo K, Hakim J, Mugyenyi P,
Henostroza G, Leger PD, Lama JR, Mohapi L, Alave J, Mave V, Veloso VG, Pillay
S, Kumarasamy N, Bao J, Hogg E, Jones L, Zolopa A, Kumwenda J, Gupta A.
Empirical tuberculosis therapy versus isoniazid in adult outpatients with
advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry
open-label randomised controlled trial. Lancet. 2016;387:1198–209.
36 Lawn SD, Nicol MP, Corbett EL. Effect of empirical treatment on outcomes
of clinical trials of diagnostic assays for tuberculosis. Lancet Infect Dis. 2015;
15:17–8.
37 Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for
us (in the short term)? Evidence for a “trial effect”. J Clin Epidemiol. 2001;54:
217–24.
38 Ravens-Sieberer U, Wille N, Badia X, Bonsel G, Burström K, Cavrini G, Devlin
N, Egmar A-C, Gusi N, Herdman M, Jelsma J, Kind P, Olivares PR, Scalone L,
Greiner W. Feasibility, reliability, and validity of the EQ-5D-Y: results from a
multinational study. Qual Life Res. 2010;19:887–97.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Gupta-Wright et al. BMC Infectious Diseases  (2016) 16:501 Page 11 of 11
